EP Patent

EP2387996A1 — Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation

Assigned to Sanofi SA · Expires 2011-11-23 · 14y expired

What this patent protects

Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events notably stroke, acute coronary syndrome or cardiovascular death in patients with permanent atrial fibrillation.

USPTO Abstract

Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events notably stroke, acute coronary syndrome or cardiovascular death in patients with permanent atrial fibrillation.

Drugs covered by this patent

Patent Metadata

Patent number
EP2387996A1
Jurisdiction
EP
Classification
—
Expires
2011-11-23
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.